TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
This phase IIa trial studies the side effects and how well TGR-1202 and ibrutinib work in
treating patients with diffuse large B-cell lymphoma that has returned after a period of
improvement or does not respond to treatment. TGR-1202 and ibrutinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth.